SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 01 2023
Historique:
received: 09 11 2021
accepted: 04 01 2023
entrez: 10 1 2023
pubmed: 11 1 2023
medline: 13 1 2023
Statut: epublish

Résumé

As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host factors expressed by the Cystic Fibrosis epithelia may influence coronavirus disease 2019 progression, here we describe the expression of SARS-CoV-2 receptors in primary airway epithelial cells. We show that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. Consistently, our results indicate that dysfunctional CFTR channels alter susceptibility to SARS-CoV-2 infection, resulting in reduced viral entry and replication in Cystic Fibrosis cells. Depending on the pattern of ACE2 expression, the SARS-CoV-2 spike (S) protein induced high levels of Interleukin 6 in healthy donor-derived primary airway epithelial cells, but a very weak response in primary Cystic Fibrosis cells. Collectively, these data support that Cystic Fibrosis condition may be at least partially protecting from SARS-CoV-2 infection.

Identifiants

pubmed: 36627352
doi: 10.1038/s41467-023-35862-0
pii: 10.1038/s41467-023-35862-0
pmc: PMC9830623
doi:

Substances chimiques

Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6
Receptors, Virus 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
ACE2 protein, human EC 3.4.17.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

132

Informations de copyright

© 2023. The Author(s).

Références

iScience. 2021 Jul 23;24(7):102770
pubmed: 34189428
J Cyst Fibros. 2021 Jul;20(4):566-577
pubmed: 34016559
FEBS Lett. 1997 Jan 6;400(3):341-4
pubmed: 9009227
Virus Res. 2009 Jun;142(1-2):19-27
pubmed: 19185596
Am J Physiol Cell Physiol. 2011 Oct;301(4):C872-85
pubmed: 21753184
J Biol Chem. 2009 Oct 9;284(41):28306-28318
pubmed: 19643730
Microorganisms. 2021 Aug 26;9(9):
pubmed: 34576716
J Biol Chem. 1998 Jul 31;273(31):19797-801
pubmed: 9677412
Molecules. 2017 Dec 29;23(1):
pubmed: 29286300
J Clin Med. 2020 Nov 10;9(11):
pubmed: 33182847
J Cyst Fibros. 2019 Jul;18(4):476-483
pubmed: 30563749
J Clin Invest. 2002 Dec;110(11):1651-8
pubmed: 12464670
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Am J Respir Cell Mol Biol. 2011 Jan;44(1):74-82
pubmed: 20167933
Pediatr Pulmonol. 2005 Jul;40(1):15-21
pubmed: 15858808
Respir Med. 2020 Aug - Sep;170:106062
pubmed: 32843180
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Curr Opin Pharmacol. 2022 Jun;64:102214
pubmed: 35453033
Biomedicines. 2021 Jan 26;9(2):
pubmed: 33530577
Pediatr Pulmonol. 2018 Nov;53(S3):S30-S50
pubmed: 29999593
J Immunol. 2013 Apr 1;190(7):3354-62
pubmed: 23436935
Mol Ther. 2020 Apr 8;28(4):1190-1199
pubmed: 32059764
Nature. 2021 Jun;594(7861):88-93
pubmed: 33827113
PLoS One. 2021 May 13;16(5):e0251527
pubmed: 33984027
Cells. 2022 Apr 15;11(8):
pubmed: 35456026
JCI Insight. 2020 Jul 9;5(13):
pubmed: 32544099
J Biol Chem. 2002 Jul 12;277(28):25377-84
pubmed: 11994290
Molecules. 2020 Apr 05;25(7):
pubmed: 32260566
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Cyst Fibros. 2011 Sep;10(5):370-6
pubmed: 21752728
Sci Rep. 2016 Jun 09;6:27390
pubmed: 27278076
BMC Pulm Med. 2022 Mar 24;22(1):101
pubmed: 35331203
J Cell Sci. 2012 Mar 1;125(Pt 5):1106-17
pubmed: 22302988
FASEB J. 2021 Apr;35(4):e21441
pubmed: 33749902
Clin Exp Immunol. 2021 Sep;205(3):391-405
pubmed: 34031873
ERJ Open Res. 2021 Dec 27;7(4):
pubmed: 34984210
J Cyst Fibros. 2020 Nov;19(6):872-874
pubmed: 32828701
Infection. 2022 Jun;50(3):671-679
pubmed: 34874541
Virus Res. 2007 Sep;128(1-2):1-8
pubmed: 17532082
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Am J Physiol Cell Physiol. 2011 Apr;300(4):C723-42
pubmed: 21209361
Crit Rev Microbiol. 2017 Nov;43(6):690-708
pubmed: 28340310
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
Nat Commun. 2015 Feb 04;6:6201
pubmed: 25648527
Int Rev Immunol. 2022;41(2):217-230
pubmed: 33616462
Immunity. 2017 Dec 19;47(6):1169-1181.e7
pubmed: 29246444
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Cyst Fibros. 2010 Sep;9(5):371-5
pubmed: 20659818
J Physiol. 2005 Dec 1;569(Pt 2):601-15
pubmed: 16210354

Auteurs

Valentino Bezzerri (V)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Section of Clinical Biochemistry, University of Verona, Verona, Italy.

Valentina Gentili (V)

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.

Martina Api (M)

Cystic Fibrosis Center of Ancona, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.

Alessia Finotti (A)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.

Chiara Papi (C)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.

Anna Tamanini (A)

Section of Molecular Pathology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Christian Boni (C)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Elena Baldisseri (E)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Debora Olioso (D)

Section of Clinical Biochemistry, University of Verona, Verona, Italy.

Martina Duca (M)

Cystic Fibrosis Center of Ancona, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy.

Erika Tedesco (E)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Sara Leo (S)

Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Monica Borgatti (M)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.

Sonia Volpi (S)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Paolo Pinton (P)

Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Giulio Cabrini (G)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.

Roberto Gambari (R)

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.

Francesco Blasi (F)

Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Giuseppe Lippi (G)

Section of Clinical Biochemistry, University of Verona, Verona, Italy.

Alessandro Rimessi (A)

Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy.
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Roberta Rizzo (R)

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.

Marco Cipolli (M)

Cystic Fibrosis Center of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. marco.cipolli@aovr.veneto.it.
Center on Innovative Therapies for Cystic Fibrosis, University of Ferrara, Ferrara, Italy. marco.cipolli@aovr.veneto.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH